comparemela.com
Latest Breaking News On - Nct03005782 - Page 1 : comparemela.com
Dr Ikegawa on An Analysis of Rapidly Manufactured Durcabtagene Autoleucel in R/R Multiple Myeloma
Shuntaro Ikegawa, MD, PhD, discusses results from a correlative analysis of an ongoing phase 1 trial evaluating the use of a novel T-Charge rapid manufacturing platform for the production of durcabtagene autoleucel CAR T-cells in multiple myeloma.
Onclive-tv
Virginia-cancer-specialists-research-institute
Fianlimab
Cemiplimab
Libtayo
Advanced-melanoma
Nct03005782
Ongoing-phase-1-trial-nct04318327-
Fianlimab Plus Cemiplimab Produces Durable Responses in Advanced Melanoma
Omid Hamid, MD, discusses the key efficacy and safety findings for the combination of fianlimab plus cemiplimab in patients with advanced melanoma.
California
United-states
Los-angeles
Omid-hamid
Translational-research
Regeneron-pharmaceuticals-inc
Research-institute
Melanoma-therapeutics
Angeles-clinic
Regeneron-pharmaceuticals
The-combination-of-fianlimab-and-cemiplimab
Nct03005782
vimarsana © 2020. All Rights Reserved.